These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 22292378)

  • 41. [A discussion of key issues on postmarketing reevaluation of Chinese medicine].
    Xie Y; Tian F
    Zhongguo Zhong Yao Za Zhi; 2010 Jun; 35(11):1494-7. PubMed ID: 20822029
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Technical challenges in designing post-marketing eCRFs to address clinical safety and pharmacovigilance needs.
    Lu Z
    Contemp Clin Trials; 2010 Jan; 31(1):108-18. PubMed ID: 19900576
    [TBL] [Abstract][Full Text] [Related]  

  • 43. The role of data mining in pharmacovigilance.
    Hauben M; Madigan D; Gerrits CM; Walsh L; Van Puijenbroek EP
    Expert Opin Drug Saf; 2005 Sep; 4(5):929-48. PubMed ID: 16111454
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Issues with regulatory pharmacovigilance in East European countries: the industry perspective.
    Hanzl-Dujmović I; Sulić-Milisić Z; Staresinić-Sernhorst I
    Toxicol Lett; 2007 Feb; 168(3):228-35. PubMed ID: 17161561
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Contribution of Latin America to pharmacovigilance.
    González JC; Arango VE; Einarson TR
    Ann Pharmacother; 2006; 40(7-8):1394-99. PubMed ID: 16868216
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacovigilance and new essential drugs in Africa: Zambia draws lessons from its own experiences and beyond.
    Huff-Rousselle M; Simooya O; Kabwe V; Hollander I; Handema R; Mwango A; Mwape E
    Glob Public Health; 2007; 2(2):184-203. PubMed ID: 19280399
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Pharmacovigilance of vaccines].
    Autret-Leca E; Bensouda-Grimaldi L; Jonville-Béra AP; Beau-Salinas F
    Arch Pediatr; 2006 Feb; 13(2):175-80. PubMed ID: 16343870
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of two drug safety signals in a pharmacovigilance data mining framework.
    Tubert-Bitter P; Bégaud B; Ahmed I
    Stat Methods Med Res; 2016 Apr; 25(2):615-29. PubMed ID: 23070598
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Decision support methods for the detection of adverse events in post-marketing data.
    Hauben M; Bate A
    Drug Discov Today; 2009 Apr; 14(7-8):343-57. PubMed ID: 19187799
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Regarding: Rosenthal DI, Glatstein E. "We've Got a Treatment, but What's the Disease?" The Oncologist 1996;1.
    Lunsford LD; Flickinger JC; Larson D
    Oncologist; 1997; 2(1):59-61. PubMed ID: 10388030
    [TBL] [Abstract][Full Text] [Related]  

  • 51. [Diagnostic kits in parasitology: which controls?].
    Rossi P
    Parassitologia; 2004 Jun; 46(1-2):145-9. PubMed ID: 15305705
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Assessment of utilization and pharmacovigilance based on spontaneous adverse event reporting of gadopentetate dimeglumine as a magnetic resonance contrast agent after 45 million administrations and 15 years of clinical use.
    Knopp MV; Balzer T; Esser M; Kashanian FK; Paul P; Niendorf HP
    Invest Radiol; 2006 Jun; 41(6):491-9. PubMed ID: 16763467
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Application of regular expression in extracting key information from Chinese medicine literatures about re-evaluation of post-marketing surveillance].
    Wang Z; Xie Y; Wang Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2888-90. PubMed ID: 22292393
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Prediction of black box warning by mining patterns of Convergent Focus Shift in clinical trial study populations using linked public data.
    Ma H; Weng C
    J Biomed Inform; 2016 Apr; 60():132-44. PubMed ID: 26851401
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Implemented data mining and signal management systems on spontaneous reporting systems' databases and their availability to the scientific community - a systematic review.
    de Almeida Vieira Lima LM; Nunes NG; da Silva Dias PG; Marques FJ
    Curr Drug Saf; 2012 Apr; 7(2):170-5. PubMed ID: 22873501
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Use of data mining at the Food and Drug Administration.
    Duggirala HJ; Tonning JM; Smith E; Bright RA; Baker JD; Ball R; Bell C; Bright-Ponte SJ; Botsis T; Bouri K; Boyer M; Burkhart K; Condrey GS; Chen JJ; Chirtel S; Filice RW; Francis H; Jiang H; Levine J; Martin D; Oladipo T; O'Neill R; Palmer LA; Paredes A; Rochester G; Sholtes D; Szarfman A; Wong HL; Xu Z; Kass-Hout T
    J Am Med Inform Assoc; 2016 Mar; 23(2):428-34. PubMed ID: 26209436
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Developing a pharmacovigilance system in the Philippines, a country of diverse culture and strong traditional medicine background.
    Hartigan-Go K
    Toxicology; 2002 Dec; 181-182():103-7. PubMed ID: 12505293
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [To explore evidence evaluation for harm: establishing the body of evidence for harm for postmarketing traditional Chinese medicine].
    Liao X; Xie YM; Wang YY; Nicola R
    Zhongguo Zhong Yao Za Zhi; 2015 Dec; 40(24):4723-7. PubMed ID: 27245012
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Key elements of design about PPK of Chinese medicine after marketing].
    Wang J; Jiang J; Xie Y
    Zhongguo Zhong Yao Za Zhi; 2011 Oct; 36(20):2871-3. PubMed ID: 22292388
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Using patient-reported experiences for pharmacovigilance?
    Adams SA
    Stud Health Technol Inform; 2013; 194():63-8. PubMed ID: 23941932
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.